

Reference number(s)

1785-A

Specialty Guideline Management Erivedge

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Erivedge	vismodegib

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication¹

Erivedge is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.

Compendial Uses²

- Basal cell carcinoma
- Adult medulloblastoma

All other indications are considered experimental/investigational and not medically necessary.

CF_RxCriteria_ERIVEDGE_1785-A.docx

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Coverage Criteria

Basal Cell Carcinoma (BCC)1,2

Authorization of 12 months may be granted for treatment of advanced, diffuse (e.g., Gorlin syndrome), recurrent, nodal, or metastatic basal cell carcinoma, as a single agent.

Adult Medulloblastoma²

Authorization of 12 months may be granted for treatment of recurrent adult medulloblastoma in patients who have received prior systemic therapy and whose tumor(s) have mutations in the sonic hedgehog pathway, as a single agent.

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

References

- 1. Erivedge [package insert]. South San Francisco, CA: Genentech USA, Inc.; March 2023.
- 2. The NCCN Drugs & Biologics Compendium™ © 2024 National Comprehensive Cancer Network, Inc. https://www.nccn.org. Accessed November 11, 2024.